Hosted on MSN10mon
Improving cancer immunotherapy by prolonging T-cell survivalThe study showed that T-cells expressing the cell receptor CD38 were more susceptible to exhaustion. Using an anti-CD38 antibody, the research team was able to block CD38 and overcome T-cell ...
During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...
Medpage Today on MSN4mon
Overcoming the Challenges of Applying CAR T-Cell Therapy to Solid TumorsSubsequently, CAR T-cell therapies for multiple myeloma received FDA approval. Currently available agents target CD38, ...
Company AnnouncementJohnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture ...
A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, respectively, with Genmab pointing to "deeper responses" with the new drug and a ...
The bispecific antibody targets GPRC5D – which is overexpressed on myeloma cells ... which includes CD38 antibody Darzalex (daratumumab) and two BCMA-targeting therapies, CAR-T Carvykti ...
Investing.com -- Genmab (CSE: GMAB) (NASDAQ: GMAB) announced on Monday, March 10, that Johnson & Johnson (NYSE: JNJ) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback